Tradewind BioScience

Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunit

shared product terms: therapeutic, immune, system, attack; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity thro

shared product terms: immune, system, cancer, cell; shared product theme: health and clinical care; shared affiliation: Y Combinator

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in

shared product terms: target, enable, cancer, cell; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmu

shared product terms: target, cancer, enable, immune; shared affiliation: Y Combinator

We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.

shared product terms: cancer, therapeutic, immune, system; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

We turn natural Language into Multi-Drone Mission execution. Degla is built around a simple idea: once you’ve expressed your intent, the system owns the problem.You don’t babysit drones. You don’t micromanage failures. You don’t rewrite plans. You state the goal, Degla figures out how.

shared extracted concept terms: natural, system; shared product terms: system, natural; shared affiliation: Y Combinator